Cagrilintide

What it is (in plain language)
- While most weight loss peptides focus on GLP-1 (blood sugar), Cagrilintide focuses on amylin. Amylin is a hormone that the body produces to signal prolonged satiety. It slows down gastric emptying and 'tells' the brain that the stomach is full for much longer, drastically reducing calorie intake.

Why do you appear online so much
- It has gained enormous traction as Semaglutide's 'ideal partner'. Studies show that the combination of the two produces greater weight loss than either alone. It is seen as the future of protocols to combat resistant obesity.

How it is framed today (pragmatic view)
- 1) Evidence: Phase II and III clinical trials show robust efficacy in humans. 2) Objective: Aggressive weight loss and control of hedonic appetite (eating for pleasure). 3) Risk: Nausea and gastrointestinal problems are common if titration is not strict.

How to use this form
- Check out the synergies section to understand how this compound interacts with GLP-1 agonists.

- Quick profile (curated by Subject 157)
- Class: Metabolic
- Status: Verified
- Use case: Fat Loss
- Route: Injectable
- Tags: Injectable|Fat Loss|Next-Gen
- Half-life: ~7 Days
- Start: 24h
- Duration: 7 days

- Mechanism (high level)
Amylin receptor agonist (co-secreted with insulin). Increases satiety via pathways other than GLP-1, allowing for powerful synergy.

- Evidence (what the literature covers)
RESEARCH RANGE (Phase 3, Non-prescriptive):
In combination tests with Semaglutide (CagriSema).
Level of Evidence: A (Preliminary).

- Safety and harm-reduction (non-prescriptive)
Risks: Gastrointestinal discomfort.
Hypoglycaemia if combined aggressively.
Interactions: Other antidiabetics.

- References (anchors)
- Enebo, L. (2021) - Safety of Cagrilintide - https://doi.org/10.1016/S0140-6736(21)00845-X
- PubMed:33909991

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.